News and Publications

 

Propria’s engineered heart tissue technology has contributed substantially to scientific presentations and peer-reviewed publications in recent years.

January 2024

Classifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches

January 2024

Cardiac Localized Polycystin-2 plays a Functional Role in Natriuretic Peptide Production and its Absence Contributes to Hypertension

November 2023

Abstract 17931: Auxotonic MyoPod® Engineered Heart Tissues Enable Longitudinal Tracking of in vitro Development of Hypertrophic Cardiomyopathy

November 2023

American Heart Association Scientific Sessions -Rapid Fire Oral: EDG-7500, a Cardiac Sarcomere Regulator That Preserves Intrinsic Myosin-Motor Function, Improves Cardiac Function and Reserve in a Minipig Model of Hypertrophic Cardiomyopathy

November 2023

American Heart Association Scientific Sessions - Poster: Acute Treatment With Aficamten Rescues Contractile Function in a MyoPod® Engineered Heart Tissue Model of Hypertrophic Cardiomyopathy

October 2023

Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy

October 2023

Evaluation of Porcine Psoas Major as a Scaffold Material for Engineered Heart Tissues

March 2023

Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy

February 2023

Modeling Hypertrophic Cardiomyopathy Due to MYBPC3 Haploinsufficiency with Engineered Heart Tissues

January 2023

Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TPM1 variant S215L

November 2022

Abstract P1056: Stretch Reduces Inter-filament Spacing And Triggers Alterations In Thick-filament Structure In Healthy Left-atrial Fibers

September 2022

Physiological calcium combined with electrical pacing accelerates maturation of human engineered heart tissue

April 2022

Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy

March 2022

GSK-3β Localizes to the Cardiac Z-Disc to Maintain Length Dependent Activation

May 2022

Multiscale Modeling of Familial Cardiomyopathy-linked Tropomyosin Mutations

November 2021

Abstract 14185: Acute Pacing Regimen Strengthens Engineered Human Cardiac Tissue

September 2021

Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation

March 2021

Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue

November 2020

Fast-relaxing cardiomyocytes exert a dominant role in the relaxation behavior of heterogeneous myocardium

November 2020

Shortening Velocity Causes Myosin Isoform Shift in Human Engineered Heart Tissues

June 2020

Contractile work directly modulates mitochondrial protein levels in human engineered heart tissue

January 2020

Modular design of a tissue engineered pulsatile conduit using human induced pluripotent stem cell-derived cardiomyocytes

Jun 2019

Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmoplakin degradation

Request Information

If you have any questions or would like more information about Propria,
please fill out the form below.